Treatment of Erythroderma Due to Pityriasis Rubra Pilaris
When erythroderma arises in the context of pityriasis rubra pilaris, the underlying condition shapes both the diagnosis and the first-line treatment approach. This page outlines the clinical scenario and points to the full structured regimen.
Clinical Scenario
Erythroderma due to pityriasis rubra pilaris represents a severe form of this dermatological condition. Exfoliative dermatitis has been associated with a severe form of pityriasis rubra pilaris in a meaningful subset of affected patients.
Treatment Goal
The primary objective is clinical remission of erythroderma. Achieving this requires systemic therapy selected and titrated according to the full structured protocol, with gradual reduction once remission is established.
Treatment Approach (Partial Overview)
First-line management involves systemic oral therapy — in this context, an oral retinoid is among the established options. The complete regimen, including selection between available agents, individualised dosing, monitoring, and the tapering schedule after remission, is detailed in the full protocol below.
References
- Exfoliative dermatitis has been related to a severe form of pityriasis rubra pilaris in 1.25% to 8.2% of cases.
- Acitretin 0.3-0.75 mg/kg/day slowly reduced after remission
- Methotrexate 10-25 mg/week slowly reduced after remission
DOI: 10.1016/j.adengl.2018.05.033
View source ↗